Ulcerative colitis is a chronic condition that causes inflammation and sores in the lining of the large intestine (colon) and rectum. It can affect anyone, but often starts in young adulthood. Understanding and managing ulcerative colitis is important because it can significantly impact a person's quality of life and carries risks if left untreated.
Ulcerative colitis is an idiopathic chronic inflammatory bowel disease characterized by continuous inflammation of the colonic mucosa, typically starting in the rectum and extending proximally in a continuous pattern. Pathophysiology involves dysregulation of the immune system, leading to mucosal damage, ulceration, and impaired barrier function.
| Condition | Distinguishing Feature |
|---|---|
| Crohn's Disease | Crohn's can affect any part of the GI tract (mouth to anus) and is characterized by transmural, discontinuous ('skip') lesions, unlike the continuous mucosal inflammation of UC. |
| Infectious Colitis (e.g., C. difficile, Salmonella, Shigella) | Infectious colitis is typically acute, often associated with fever and a preceding exposure, and may resolve with antibiotics, whereas UC is chronic and relapsing. |
| Irritable Bowel Syndrome (IBS) | IBS is a functional disorder without objective evidence of inflammation or mucosal damage; it does not typically cause bloody diarrhea or significant weight loss. |
| Ischemic Colitis | Ischemic colitis usually occurs in older adults with vascular risk factors and presents with sudden onset abdominal pain followed by bloody diarrhea; it affects watershed areas of the colon. |
| Diverticular Disease | Diverticular disease typically causes left lower quadrant pain and may be associated with bleeding, but not usually chronic bloody diarrhea or diffuse colonic inflammation. |
| Radiation Proctitis/Colitis | History of pelvic radiation therapy is key; symptoms may be similar to UC but are localized to the irradiated field. |
Management of ulcerative colitis is individualized and aims to induce and maintain remission, improve quality of life, and prevent complications. Treatment modalities include 5-aminosalicylic acid (5-ASA) agents for mild to moderate disease, corticosteroids for flares, immunomodulators, and biologic therapies (e.g., anti-TNF agents, vedolizumab) for moderate to severe or refractory disease.